This week in therapeutics

Indication	Target/marker/ pathway	Summary	Licensing status	Publication and contact information
Cancer				
Acute lymphoblastic leukemia (ALL)	Wolf-Hirschhorn syndrome candidate 1 (WHSC1; MMSET; NSD2)	Cell culture studies suggest inhibiting MMSET could help treat patients carrying activating mutations in the protein. In an analysis of the cancer cell line encyclopedia, an E1099K mutation in MMSET was identified in eight cell lines, seven of which were of lymphoid origin. The mutant MMSET cell lines displayed globally increased lysine H3K36 dimethylation compared with wild-type MMSET cell lines. Next steps include functional studies to test whether blocking MMSET activity could help treat cancers carrying the mutation.	Unpatented; licensing status not applicable	Oyer, J.A. <i>et al. Leukemia</i> ; published online July 26, 2013; doi:10.1038/leu.2013.204 Contact: Relja Popovic, Northwestern University, Chicago, Ill. e-mail: r-popovic@northwestern.edu Contact: Jonathan D. Licht, same affiliation as above e-mail: j-licht@northwestern.edu
SciBX 6(38); doi:10.1038/scibx.2013.1054 Published online Oct. 3, 2013				